The Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place on 30 September 2026, will bring together experts from across the drug discovery ecosystem to examine the scientific, operational and commercial developments shaping the future of early-stage drug discovery.

Following the announcement of the preliminary speaker lineup, we are now revealing further details of three of the four sessions featured in the programme.

Beyond Borders: Building a Collaborative and Resilient Drug Discovery Ecosystem, moderated by Reece Armstrong, Editor at Drug Discovery World (DDW), will examine how companies are navigating scale-up challenges, regulatory and geographical barriers, and resource management across clinical development. Kirsten Detrick (Basel Area Business & Innovation), Shrijay Vijayan (Polaryx Therapeutics), Peter Milner (Renexxion), and Grant Carr (Curia), will share real-world perspectives on building resilience and collaboration in a turbulent market.

Working Smarter: Strategies for Improving Lab Effectiveness, moderated by Diana Turner, Deputy Editor at DDW, will explore how early-stage drug discovery professionals can improve processes, optimise workflows and become more efficient. Christine Allen (Intrepid Labs), Elodie Siney (Oxford North), and Tom Valentin (CSEM) will discuss the role of new technology in expediting drug discovery processes, and the importance of applying lean methodologies to reduce costs and get products to market sooner.

Therapies and Modalities Changing Global Drug Discovery, moderated by Megan Thomas, Content Team at DDW, will examine the rapidly evolving therapeutic landscape, including cell therapies, gene editing and RNA. Melinda Duer (University of Cambridge), Steve Wedge (Cancer Research Horizons), Louise Modis (Amphista Therapeutics), and Caroline Barelle (Elasmogen) will explore the modalities having the biggest impact, how research and commercial planning are managed in these areas, and how advanced scientific approaches are creating new opportunities and addressing hard-to-treat diseases.

Where Next? Emerging Markets, Capital Flow and the New Frontiers of Drug Discovery, moderated by Patrik Frei, Founder and CEO of Venture Valuation Inc and Biotechgate, will explore the emerging therapeutic areas and technologies shaping the future of drug discovery, and examine where capital is flowing across Europe, the US and China. Julia Moore (Breakout Ventures), Johnny Habchi (Medicines Discovery Catapult), and Reuben Dawkins (Link Biologics) will share insights into the current financing landscape, evolving preferences across funding stages, and practical advice for biotech companies seeking investment.

These three sessions form part of the four-session programme. Further details on the final panel will be announced shortly.

The Forum is available to delegates across two regional time blocks – one timed for Europe and one for the Americas. Registration is open for both the Europe and Americas sessions, allowing attendees to join the programme at a time that suits their region.

Register here for Europe Forum: https://event.gotowebinar.com/event/bab960cb-c367-42c1-b4f5-9b8c0c9e6acd

Register here for Americas Forum: https://event.gotowebinar.com/event/36348c15-804c-4f9a-8b43-e67bd9c449b6

The Digital Forum is supported by Lead Sponsor Curia.